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SUMMARY A great deal of pharmaceutical research is nowadays carried out in developing coun-
tries such as Pakistan. Is it, however, beneficial for the country and the participants, often the poorly 
educated and illiterate? Pharmaceutical research in Pakistan can bring benefits to both patients and 
country. Promotion of good clinical practice and the development of national guidelines are advocated. 
Government and industry both have a role to play to maintain the right balance.
Recherche pharmaceutique : paradoxe, défi ou dilemme ?
RÉSUMÉ Une grande partie de la recherche pharmaceutique est réalisée de nos jours dans des pays 
en développement tels que le Pakistan. Cependant, le pays et les participants, qui souvent sont les 
personnes ayant peu d’instruction et illettrées, en tirent-ils un quelconque bénéfice ? La recherche 
pharmaceutique au Pakistan peut procurer des avantages aux patients ainsi qu’au pays. La promotion 
des bonnes pratiques cliniques et l’élaboration de lignes directrices nationales sont préconisées. Le 
gouvernement et l’industrie ont tous deux un rôle à jouer pour maintenir le juste équilibre.
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Introduction
Globalization of health research and the 
conduct of clinical trials involving human 
participants over the past few decades has 
highlighted a number of ethical issues, 
especially in those situations in which or-
ganizations sponsoring research carry out 
studies in other countries. These may be 
done as a way of helping the host country 
address a public health problem; the re-
search sponsor may consider the foreign 
location more convenient, more efficient, 
or less troublesome for a specific study; or 
the study may be carried out as a joint effort 
to address a specific health concern that is 
important in both countries. 
The pace and scope of international 
collaboration in biomedical research have 
increased during the past few years, and 
now questions about the ethics of designing, 
conducting, and following up clinical trials 
have re-emerged. There is concern that 
research done by scientists from the richer 
countries but carried out in poorer nations 
that are heavily burdened by disease may 
be seen as imposing ethically inappropri-
ate burdens on the host country and on 
the participants themselves. The potential 
for exploitation has engendered efforts to 
ensure that those who participate in interna-
tional clinical trials are protected. 
Pakistan is one of the developing coun-
tries where balance still needs to be attained 
between supply and demand in health care. 
Health care spending is escalating at a rate 
of US$ 0.3 billion per annum, which trans-
lates in to US$ 100 million per annum rise 
in pharmaceutical sales [1]. Unfortunately, 
the number of physicians per 1000 popula-
tion remains static [1]. This is an indicator 
of the enormous burden of health care ex-
penditure on the Indian subcontinent, where 
per capita annual income is equivalent to 
about $US 400. The public health system 
receives 0.8%–4.0% of the gross national 
product [2] (compared with 10%–15% in 
developed countries [3]). These hard facts, 
coupled with the general lack of third-party 
health insurance, mean that < 40% of our 
population has access to pharmaceuticals 
[1]. 
The major portion of our population, 
therefore, relies on alternative medicine, 
primarily practised by sidewalk practitio-
ners, e.g. people practising the homeopathic 
system or unani tibb (Greek medicine); 
herbal or traditional healers; and spiritual 
healers (pirs, aamils, etc).
The pharmaceutical industry 
and research
The market in Pakistan
The role of the pharmaceutical industry 
needs to be explored. The Pakistani pharma-
ceutical market is estimated to be US $1.25 
billion. There are 35 000 pharmaceuticals 
registered in the country [4]; prepackaged 
and formulated preparations are the main-
stay of the industry. The usage, distribution, 
dispensing and administration monitoring 
aspects go unchecked, and the primary focus 
remains on production. The main share of 
the market is enjoyed by antibiotics (28%), 
followed by gastrointestinal drugs (14%) 
and respiratory medications (8%) . 
The market shares of multinational and 
indigenous companies are converging quite 
rapidly. It could be depicted as an approxi-
mate 5% loss in local market share annually 
for the multinational companies, which are 
rapidly being overtaken by the local phar-
maceutical companies. An analysis of the 
7-year period 1998–2005 clearly shows a 
shift of market share from 30:70 to 50:50 
for local and multinational companies. The 
annual growth rate for the Pakistani phar-
maceutical market is estimated to be 5%, 
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with a 10% rise in institutional sales. This 
has a far-reaching impact on the research 
that is conducted in the country, and also 
on the quality of pharmaceuticals in clinical 
research.
Challenge: research and 
development
Most of the developing countries lack active 
research and development laboratories. The 
majority of industrial processing revolves 
around packaging and formulation. This, of 
course, leaves the pharmaceutical compa-
nies, primarily the multinational companies 
but some local ones too, at an advantage 
and allows them to proliferate in this area: 
research and development remains solely 
their realm. The research and development 
of a drug needs 3–4 times more capital 
today compared to 10–15 years ago. The 
graphical representation of the research and 
development expenditure of developed na-
tions, particularly Japan, the United States 
of America and the European countries, 
provides a fair idea about this rise. Between 
1990 and 2004, expenditure on drug re-
search and development in Europe rose from 
7941 to 21 500 million euros. In the United 
States of America during the same period, it 
rose from 6015 to 27 095 million euros, and 
in Japan from 1990 to 2003 expenditure rose 
from 3941 to 6743 million euros.”
While analysing the data, it should be 
remembered that marketing expenditures 
are always embedded with research and 
development activities. A breakdown of 
research and development activities of 9 
top pharmaceutical companies shows that 
30% of expenditure is used for discovery 
research and 35% for clinical evaluation; 
22 % is accounted for by non-clinical evalu-
ation [5]. This 22% of the expenditure could 
be linked to marketing investment. 
Additionally, when comparing the phar-
maceutical industry with other industries, 
the research and development expenditure 
is proclaimed to be much higher [5]. This 
could be a result of the large marketing 
expenses component, which is obviously 
not an element of core research.
Paradox
The number of trials conducted in the devel-
oping countries is lamentable: 90% of medi-
cal research funds are spent on the richest, 
i.e. 10% of the world’s population [6], and 
research and development expenditure for 
diseases of poverty (e.g. malaria, tropical 
diseases, tuberculosis etc.) is regarded as 
high risk (failure) and providing low re-
turns. Drug trials in developing countries 
are usually initiated outside the country 
and dominated by the partner from the de-
veloped country, for example, Pharmacia-
Upjohn has a research and development 
budget of US$ 2.2 billion per year, but only 
6% is spent in Asia, mainly in Singapore, 
Taiwan, Hong Kong and Korea [7]. In his 
1999 article, Silverstein says, “Many peo-
ple of the Third World die of preventable, 
curable diseases. … malaria, tuberculosis, 
acute lower-respiratory infections claim-
ing 6.1 million lives in 1998. People die 
because the drugs to treat those illnesses 
are nonexistent or are no longer effective, 
and they die because it doesn’t pay to keep 
them alive” [7]. 
This unequal equation of overlooking 
diseases of the poor can be well illustrated 
when one identifies the origin of research 
money: in the United States of America, 
70% of research is funded by industry and 
only 30% by the National Institute of Health 
[8]. It would be interesting to know the 
fringe benefits involved in the sponsored 
trials fuelled by the research and develop-
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ment expenditure. The following rates will 
definitely serve as an eye opener [9–11]: 
• paid speaking arrangements: ranging 
from $250 to $20 000/year; 
• paid consultancies: mostly less than 
$10 000 but may be up to $120 000/
year; 
• paid positions on advisory boards, eq-
uity holdings: mostly over $10 000 and 
ranging up to $1 million/year. 
Apart from these overwhelming incen-
tives, the “luncheons” should not be left 
unaddressed. Across the United States of 
America, as a part of their research efforts, 
drug companies sponsor close to 300 000 
events for doctors every year, many of them 
far more generous than a free pizza [10]. 
Dilemma
Millions of people die from preventable or 
curable diseases every week. But there is 
no market in the sense that, unlike Viagra, 
medicines for leishmaniasis are needed by 
poor people in poor countries. Pharmaceuti-
cal companies judge that they would not get 
sufficient return on research investment, so 
why, they ask, should they bother? Their ob-
ligation to shareholders, they say, demands 
that they put their effort into trying to find 
cures for the diseases of affluence and lon-
gevity: heart disease, cancer, Alzheimer’s. 
Of the thousands of new compounds drugs 
companies have brought onto the market 
in recent years, less than 1% have been for 
tropical diseases [12]. 
Pharmaceutical companies may not be 
altruistic, but they may still have a powerful 
reason for sticking to ethical practices: “It’s 
not in anyone’s interest to do anything that 
would ultimately result in a drug being re-
called,” said Kate Robins, a spokeswoman 
for Pfizer. “You wouldn’t spend a billion 
dollars if you’re going to cut corners and 
it’s going to ultimately be recalled. You’re 
going to go into places where you can hold 
up to standards that are international,” she 
said [13]. “There is no easier, softer way. 
There just isn’t.”
Drug trials in developing 
countries
Another area of concern regarding clinical 
trials is the vertical transmission trials con-
ducted in a variety of developing countries 
by researchers from more-developed coun-
tries. These illustrate a variety of ethical 
issues. Three crucial issues are the injustice 
of the use of placebo control groups, the 
coercion used to recruit participants, and 
the exploitation of developing countries. A 
2002 study examined each of these issues 
separately. It developed a new standard for 
when placebo control groups are acceptable 
and concluded that the issue of coercive of-
fers was not well founded. and that concerns 
about exploitation are better addressed by 
assurances about the future care of the par-
ticipants in the trial than by assurances of 
availability of the drugs in the country in 
general [14].
Against this background, it is hard to tie 
in ethics with research. Essentially, research 
requires expertise, diligence, honesty and 
integrity. Ethical research is vital to gener-
ate sound knowledge, but what does the 
ethical conduct of research involve? The 
concern regarding ethical consideration in 
research in developing countries could be 
expressed by the following questions. How 
does one obtain informed consent from 
people who cannot read and write? Who 
oversees the trials in areas where ethical 
review committees are unknown? Is the dis-
ease under investigation similar in different 
countries (epidemiological data are required 
to answer this question)? Is the trial relevant 
to the country? Are the risk factors the 
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same, is the treatment relevant and are the 
outcomes approximately the same? Do the 
culture and infrastructure exist to carry out 
this trial [15]?
The researcher may wish to stratify a 
method for obtaining genuine consent for 
participation, keeping in mind the standard 
of care locally and in developed countries. 
There is always an abundance of vulner-
able communities in developing countries, 
and this is so in Pakistan. Limited economic 
development; inadequate community/cul-
tural experience with, or understanding 
of, scientific research; limited availability 
of health care and treatment options; and 
limited ability of individuals in the commu-
nity to provide informed consent are some 
factors requiring much attention. In many 
countries, it is important for researchers to 
obtain permission from local leaders before 
seeking individual informed consent, and 
to discuss other aspects of the research. 
Although it may be difficult to identify the 
members of the community who should be 
consulted and to determine the level of au-
thority they should have to permit research-
ers to approach potential participants, we 
believe that such consultations can be help-
ful in improving both the informed consent 
process and the overall research design. 
Good clinical practice
What is the importance of good clinical 
practice? Ideally speaking, it protects the 
right of study subjects with respect to integ-
rity and confidentiality. Good clinical prac-
tice also ensures that the data-driven results 
are credible. Scientifically, clinical trials 
are carried out for the testing of hypotheses, 
registering new drugs and devices, post-
marketing surveillance in order to docu-
ment efficacy and safety, and to obtain data 
for publication. Hence, the methodology of 
the clinical trial matters a lot. Study design, 
selection of appropriate subjects, adequate 
sample size, duration of the study and ef-
fectiveness of follow-up are some important 
aspects that may reflect on the credibility of 
the results.
Good clinical practice remains essential 
no matter where the study is conducted or 
who is conducting it. The prime concern is 
why developing countries are the favoured 
location for clinical trials. The large patient 
population, low incurred costs, a legislative 
vacuum or shortcomings, ignorance about 
legal and ethical issues and a strong desire 
among the developing countries to link up 
with institutions from rich countries at any 
cost could be the most likely reasons. 
The developing countries do need clinical 
trials to be conducted—for the development 
of new medicines and regimens suitable 
for the local environment; to verify safety 
and efficacy on different ethnic groups; for 
academic interest and stimulation; and to 
generate income for institutions as well as 
individual financial reward. These are im-
portant considerations as far as developing 
countries are concerned. 
Good clinical practice in Pakistan
In Pakistan, the government has definitely 
recognized the graveness of the issue, react-
ing to it by forming in 2002/03 a Ministry 
of Health/World Health Organization com-
mittee on good clinical practice, functioning 
as a Ministry of Health Research Cell. The 
final draft of the Pakistan good clinical 
practices has been sent to the World Health 
Organization for review. 
On the part of our pharmaceutical indus-
try, some issues still need to be resolved: 
lack of infrastructure and the overwhelming 
contribution of multinational industries in 
trials disturbs the equilibrium. 
The way trials in Pakistan are conducted 
is deplorable. They are mostly phase IV 
(replicate) trials, which are more promo-
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tional than evaluative. Company-sponsored 
clinical drug trials mostly use drugs sup-
plied as samples. The majority of them are 
non-randomized, uncontrolled and open 
label. They are disguised as post-marketing 
surveillance, but in reality their anticipated 
outcome is to broaden the market share. The 
pharmaceutical companies have taken over 
the greater proportion of trials conducted; 
investigator-initiated trials and independent 
international publications are rare entities. 
As has already been mentioned, local 
institutions in developing countries, partic-
ularly Pakistan, have an interest in tagging 
along on trials run by the multinationals; 
it is, however, worth noting the situation 
of our citizens participating in the clinical 
trials. 
Access to healthcare facilities and phar-
maceuticals is still a dream for most of the 
population. The lack of third-party insur-
ance and governmental healthcare coverage 
policies may encourage people to partici-
pate in clinical trials as this may the only 
way they can obtain medical attention and 
get a chance to gain access to healthcare fa-
cilities. These poorly educated, and mostly 
illiterate, persons do not understand the 
consequences of being research subjects. 
Role of the ethical review committee
In such a scenario, where a person is not 
aware of his or her rights and safety once 
inducted into the study, the ethical review 
committee needs to play a strong role in the 
interests of the population. The dilemma is 
that the ethical review committee in a de-
veloping country may overlook the impor-
tance of the local value system and also the 
adequacy of resources. The committee may 
fail to acquire the representation of social 
scientists, ethicists and other allied health 
professionals; thus, ethical review commit-
tees remain mostly physician-driven. Prob-
lems which initially appear minor, such as 
inadequate translation of informed consent 
in national languages, may turn out to be a 
nightmare for the study participants. 
Involvement of clinicians
Clinicians have a complex relationship with 
the pharmaceutical industry, and need to 
critically evaluate their handling of sam-
ples and their contact with pharmaceutical 
company representatives to optimize this 
relationship and ensure quality patient care. 
Clinics with specific policies for interac-
tions with drug companies appear to derive 
greater satisfaction from their encounters.
Gifts, no matter how small, produce a 
sense of reciprocity in the recipient; this 
is why pharmaceutical companies provide 
pens, notepads, name badge holders, etc. 
Social science has documented the way that 
gift recipients feel impelled to do something 
in return for the giver. However, this creates 
a conflict of interests: the desire to cure 
the patient versus the subconscious need 
to repay the drug company’s generosity. 
While these 2 goals can be congruent, they 
may not be.
Entitlement is also an issue: students 
and resident physicians feel entitled to a 
good lunch and cool gadgets from the drug 
companies.
Role of the authorities
On the part of the regulatory authorities, 
a revolutionary transformation is required 
to provide the infrastructure to support re-
search, ensure standards of care and safety, 
develop guidelines/legislation and imple-
ment standards. The Government of Paki-
stan has taken the initiative to formalize 
a National Committee on Good Clinical 
Practice and Good Prescribing Practice. The 
committee is to be a guideline-formulating 
body and will be responsible for training 
the health care community by organizing 
courses and seminars.
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Conclusion
Promotion of good clinical practice in coun-
tries such as Pakistan requires mass aware-
ness and education campaigns, training 
programmes or course development, the 
development of national guidelines, gov-
ernment and health ministry involvement at 
all levels and regular monitoring to evaluate 
benefits and ensure progress. 
Pharmaceutical research is crucial to 
Pakistan. It brings benefit to the patients 
and wealth to the country. Government and 
industry have a definite role to play to keep 
the right balance between industrial policy 
and health policy. One should welcome and 
reward innovation, regulate less and better. 
The unprecedented movement between 
countries of people, goods and ideas has 
increased awareness of the imbalance in the 
global burden of disease among the citizens 
of developed countries. This is sometimes 
referred to as the 10/90 gap: less than 10% 
of global health care expenditure is devoted 
to conditions that account for 90% of the 
global burden of disease [16]. 
Initiatives to reduce the burden of dis-
ease in developing countries are urgently 
needed. Clinical trials responsive to the 
health care needs of developing countries 
are one such initiative. It is, however, nei-
ther necessary nor desirable to lower ethical 
standards in order to achieve this goal. On 
the contrary, standards should be main-
tained, and adapted specifically to the needs 
of developing countries. 
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e-Health Code of Ethics 
On Wednesday, May 24, 2000 the e-Health Ethics Initiative introduced 
a code of ethics for health care sites and services on the Internet. The 
“e-Health Code of Ethics” will help people worldwide realize the poten-
tial of the Internet for improving health and minimize its potential for 
doing harm. The e-Health Code is available in Arabic, Chinese, English, 
French, German and Spanish at: http://www.ihealthcoalition.org/. The 
Arabic version is also available on the EMRO website at: http://www.
emro.who.int/his/medicalethics.htm
